The long-term objective of this Institutional NRSA is to train a new generation of pediatric subspecialists in translational and laboratory research. The focus of the training experience will be molecular and translational medicine, defined as the use of sophisticated molecular approaches to improve diagnosis and treatment of pediatric diseases. The program is physically located on the campus of Nationwide Children's Hospital, the academic home of both The Research Institute at Nationwide Children's Hospital and the Department of Pediatrics in the College of Medicine at The Ohio State University. In recent years, there has been a substantial resource commitment to research at our institution. The Research Institute is uniquely organized into Centers of Emphasis, which purposefully dissolve the traditional academic division-based silos of research and provide for alignment of investigators and trainees based on scientific interests and needs. This unique organizational model allows the Department of Pediatrics to adopt the novel approach to subspecialty research training described herein. In brief, each of the Centers will function as a training unit and scientific community for fellows. The scientific training and mentoring for individual fellows will be the responsibility of the selected training unit (Center) and its faculty, in addition to the traditional model of a named faculty mentor. Using this unique model, we were highly successful in the first 5 years of funding. We propose to renew this NRSA and plan to train a total of 8 MD or MD/PhD pediatric scientists over the next award period. A talented cadre of senior M.D. and Ph.D. scientists have enthusiastically agreed to serve as Program Faculty. Our unique training model, combined with the organizational commitment to build a first-rate research infrastructure, places Nationwide Children's Hospital in a favorable position to offer the highest caliber subspecialty research training program possible.
Recent advances in biomedical research have created an extraordinary opportunity for advancement in prevention and treatment of diseases of childhood by molecular approaches. A major obstacle is the lack of a well-trained workforce of pediatric physician scientists. This training grant is designed to aggressively train a cadre of outstanding pediatric scientists to meet this critical need for new talent.
|Honegger, Jonathan R; Tedesco, Dana; Kohout, Jennifer A et al. (2016) Influence of IFNL3 and HLA-DPB1 genotype on postpartum control of hepatitis C virus replication and T-cell recovery. Proc Natl Acad Sci U S A 113:10684-9|
|Streby, Keri A; Shah, Nilay; Ranalli, Mark A et al. (2015) Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy. Pediatr Blood Cancer 62:5-11|
|Al-Zaidy, Samiah; Rodino-Klapac, Louise; Mendell, Jerry R (2014) Gene therapy for muscular dystrophy: moving the field forward. Pediatr Neurol 51:607-18|
|Honegger, Jonathan R; Kim, Seungtaek; Price, Aryn A et al. (2013) Loss of immune escape mutations during persistent HCV infection in pregnancy enhances replication of vertically transmitted viruses. Nat Med 19:1529-33|
|Fuh, B; Sobo, M; Cen, L et al. (2009) LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer 100:106-12|
|Luce, Wendy A; Hoffman, Timothy M; Bauer, John Anthony (2007) Bench-to-bedside review: Developmental influences on the mechanisms, treatment and outcomes of cardiovascular dysfunction in neonatal versus adult sepsis. Crit Care 11:228|
|Caldas, Hugo; Fangusaro, Jason R; Boue, Daniel R et al. (2007) Dissecting the role of endothelial SURVIVIN DeltaEx3 in angiogenesis. Blood 109:1479-89|
|Fangusaro, Jason R; Caldas, Hugo; Jiang, Yuying et al. (2006) Survivin: an inhibitor of apoptosis in pediatric cancer. Pediatr Blood Cancer 47:4-13|
|Zhao, Qun; Shepherd, Edward G; Manson, Mary E et al. (2005) The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38. J Biol Chem 280:8101-8|
|Fangusaro, J R; Jiang, Y; Holloway, M P et al. (2005) Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 92:359-65|
Showing the most recent 10 out of 11 publications